Showing results (111-120 of 147) with videos related to
Sort By:
Pageof 15
JHEP Reports : Innovation in Hepatology|August 21, 2020
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis CJun Itakura, Masayuki Kurosaki, Satoru Kakizaki, et al.Scientific Reports|April 30, 2022
Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencingFumiyasu Nakamura, Haruhiko Takeda, Yoshihide Ueda, et al.Oncogene|April 13, 2004
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cellsNaoki Kanda, Hiroshi Seno, Yoshitaka Konda, et al.The Journal of Biological Chemistry|September 13, 2013
Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)Koichi Watashi, Guoxin Liang, Masashi Iwamoto, et al.Liver Cancer|August 20, 2025
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 TrialMasatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, et al.International Journal of Cancer|August 12, 2016
TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinomaSoo Ki Kim, Yoshihide Ueda, Etsuro Hatano, et al.Carcinogenesis|February 22, 2021
Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virusHaruhiko Takeda, Atsushi Takai, Eriko Iguchi, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2021
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C VirusNobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 13, 2022
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapyToshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, et al.Journal of Medical Virology|October 12, 2022
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis BShun Kaneko, Masayuki Kurosaki, Toshie Mashiba, et al.Pageof 15